Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | November 12, 2025 | November 14, 2025 |
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | July 30, 2018 | August 01, 2018 |
| INSULET CORPPODD · Entity 3516 | Director | May 21, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,634 |
Ending reported balance
After 2025-11-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-11-12 · Exercise / conversion · Acquired 15,000 · Balance 79,634 Row 2 · 2025-11-12 · Exercise / conversion · Acquired 19,853 · Balance 99,487 Row 3 · 2025-11-12 · Sale · Disposed 34,853 · Balance 64,634 F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $16.49 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2025-11-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-12 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: The option is fully vested and exercisable. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $9.33 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2025-11-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-12 · Exercise / conversion · Disposed 19,853 · Balance 0 F2: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option is fully vested and exercisable.
EXACT SCIENCES CORP
Report date July 30, 2018 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,767 |
Reported balance
After 2018-07-30 transaction · row 1
1 source rowRow 1 · 2018-07-30 · Sale · Disposed 2,373 · Balance 33,767 F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock.
INSULET CORP
Report date May 21, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,498 |
Ending reported balance
After 2021-05-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-05-21 · Exercise / conversion · Acquired 2,235 · Balance 16,733 Row 2 · 2021-05-21 · Exercise / conversion · Acquired 3,587 · Balance 20,320 Row 3 · 2021-05-21 · Sale · Disposed 2,235 · Balance 18,085 Row 4 · 2021-05-21 · Sale · Disposed 3,587 · Balance 14,498 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.87 · Expires 2026-05-11 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-21 · Exercise / conversion · Disposed 2,235 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.60 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-21 · Exercise / conversion · Disposed 3,587 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 37,362 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 2,534 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2019 Filed Mar 22, 2019 20:16 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 5,000 | $100.00 | $500,000.00 |
DisclosureSEC source: 0001127602-19-012921 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,743 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 20:16 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,000 | $21.35 | $106,750.00 |
DisclosureSEC source: 0001127602-19-012921 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001127602-19-011377 · form4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 5,000 | $95.00 | $475,000.00 |
DisclosureSEC source: 0001127602-19-011377 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,743 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,000 | $21.35 | $106,750.00 |
DisclosureSEC source: 0001127602-19-011377 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001127602-19-010579 · form4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 10,000 | $92.64 | $926,400.00 |
DisclosureSEC source: 0001127602-19-010579 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,743 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:06 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 10,000 | $21.35 | $213,500.00 |
DisclosureSEC source: 0001127602-19-010579 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. F2 · balance_after: Includes 2,185 restricted stock units granted on May 16, 2018, which vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 2,373 | $58.86 | $139,674.78 |
DisclosureSEC source: 0001209191-18-044763 · doc4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,767 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 19:38 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044482 · doc4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,140 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 16:09 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 7,543 | $0.00 Strike: $24.45 | $0.00 |
DisclosureSEC source: 0000792977-18-000037 · wf-form4_152848854041879.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,543 Underlying: Common Stock · 7,543 shares Expires 2028-06-07 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 16:09 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0000792977-18-000037 · wf-form4_152848854041879.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,977 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 4,506 | $0.00 Strike: $24.95 | $0.00 |
DisclosureSEC source: 0001192482-18-000256 · edgar.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,506 Underlying: Common Stock · 4,506 shares Expires 2028-05-24 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2019, subject to the director's continued service with the issuer. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 2,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000256 · edgar.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,628 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:52 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018181 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,743 F1 · shares: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 22:25 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 200 | $84.17 | $16,833.00 |
DisclosureSEC source: 0001127602-18-011891 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,558 F1 · balance_after: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018; and 2,709 restricted stock units granted on May 17, 2017, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 22:25 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 8,800 | $84.10 | $740,080.00 |
DisclosureSEC source: 0001127602-18-011891 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,758 F1 · balance_after: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018; and 2,709 restricted stock units granted on May 17, 2017, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 17:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046734 · doc4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,910 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| May 24, 2017 Filed May 25, 2017 20:33 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 19,853 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0001192482-17-000135 · edgar.xml · derivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,853 Underlying: Common Stock · 19,853 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2018, subject to the director's continued service with the issuer. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:12 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 10,110 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001179110-17-007790 · edgar.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 10,110 shares Expires 2027-05-18 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:12 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 4,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-007790 · edgar.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,399 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:36 UTC | INSULET CORP PODD · Entity 3516 | GrantStock Option (Right to Buy) · Derivative | 3,587 | $0.00 Strike: $40.60 | $0.00 |
DisclosureSEC source: 0001127602-17-018705 · form4.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,587 Underlying: Common Stock · 3,587 shares Expires 2027-05-17 Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:36 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018705 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,558 F1 · shares: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.